Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has received a consensus rating of "Buy" from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $15.80.
ZURA has been the topic of several research reports. HC Wainwright reaffirmed a "neutral" rating and set a $5.00 price target on shares of Zura Bio in a report on Tuesday, December 24th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zura Bio in a research report on Wednesday, December 11th.
Read Our Latest Report on Zura Bio
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its position in shares of Zura Bio by 12,060.8% during the fourth quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company's stock worth $6,583,000 after acquiring an additional 2,611,532 shares during the last quarter. Braidwell LP acquired a new stake in Zura Bio during the 3rd quarter valued at approximately $10,040,000. Sphera Funds Management LTD. bought a new position in Zura Bio during the 3rd quarter worth approximately $2,999,000. Millennium Management LLC lifted its position in shares of Zura Bio by 1,499.0% in the 4th quarter. Millennium Management LLC now owns 701,278 shares of the company's stock worth $1,753,000 after purchasing an additional 657,420 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Zura Bio by 70.6% in the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company's stock valued at $3,706,000 after purchasing an additional 377,545 shares during the last quarter. 61.14% of the stock is owned by institutional investors and hedge funds.
Zura Bio Stock Performance
NASDAQ:ZURA traded down $0.15 during trading hours on Monday, hitting $1.08. The company's stock had a trading volume of 310,744 shares, compared to its average volume of 392,211. Zura Bio has a twelve month low of $1.08 and a twelve month high of $6.35. The stock has a fifty day simple moving average of $1.65 and a 200-day simple moving average of $2.95.
Zura Bio Company Profile
(
Get Free ReportZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Featured Stories
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
